The potential future implementation of Type II JAK inhibitors into the treatment landscape of MPNs

In this interview, Andrew Dunbar, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the potential future implementation of Type II JAK inhibitors into the treatment landscape of myeloproliferative neoplasms (MPNs), highlighting that these agents are still in early phase trials and that further data is needed to evaluate their value and side effect profiles. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.